Multi-Cancer Detection Observational Cohort Study

Launched by MAYO CLINIC · Apr 30, 2025

Keywords

ClinConnect Summary

The Multi-Cancer Detection Observational Cohort Study is a research project designed to learn more about a new type of test called Multi-Cancer Detection (MCD). This test looks for signs of cancer in the blood, which can help identify cancers that may not yet be causing symptoms. By analyzing tiny pieces of DNA from tumor cells that are found in the blood, the test aims to find out if there is a cancer present and where it might be in the body. The goal is to catch cancer early when it is more treatable.

To be eligible for this study, participants need to be at least 21 years old and have a medical record at the Mayo Clinic. They should have recently had or be scheduled to have an MCD test. Participants will need to provide a blood sample and agree to take part in the study. However, people who are currently receiving active cancer treatment (except for certain hormone therapies), have been diagnosed with invasive cancer in the past three years, or are pregnant cannot join. This study aims to improve cancer detection methods, which could lead to earlier and more effective treatment for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Has Mayo Clinic medical record number
• • Has undergone (within last 6 months) or scheduled to undergo a multi-cancer detection test (MCD) as ordered by provider
• • Able to provide informed consent
• • ≥ 21 years old
• • Ability to provide blood sample
• Exclusion Criteria:
• • Individuals who have situations that would limit compliance with the study requirements
• • Institutionalized (i.e. Federal Medical Prison)
• • Known pregnancy (self-reported)
• • Currently undergoing active cancer treatment other than adjuvant hormone therapy
• • Invasive cancer diagnosis within the last 3 years